NeurMedix, Inc.
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07J (Steroids).
The verdict
According to USPTO PatentsView, Neurmedix ranks #26,953 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 4 technology areas.
- #26,953
- of 49,997 US assignees by volume
- 11th percentile
- by Innovation Score (22.9/100)
- 12.6
- avg claims per patent
- -89%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R26953 · US Corporation #26,953 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 10 grants
- MID-PACK #26,953/49,997
- PHOTO-FINISH Nauti-Craft Pty
- CPC-NARROW C07J · 4 areas
- INNOV-THIN 22.9/100
- CLAIMS-RICH 12.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -89% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Nauti-Craft Pty Ltd (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Neurmedix’s 22.9 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Neurmedix
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- NeurMedix · this assignee 23
NeurMedix · this assignee
23 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Neurmedix's Innovation Score is 22.9/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Neurmedix?
Each dot is one of Neurmedix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neurmedix’s own 12.6 claims/patent is at or below the 19.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Neurmedix's grants concentrate
NeurMedix, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 90% of grants classified under C07J (Steroids). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2016. By volume, Neurmedix sits between Nauti-Craft Pty Ltd and Neutrolis, Inc..
Who files at NeurMedix's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nauti-craft Pty
Nauti-Craft Pty Ltd
10 patents
- Navinta
Navinta, LLC
10 patents
- Nejilaw
NejiLaw Inc.
10 patents
- Netbrain
NetBrain Technologies, Inc.
10 patents
- Neuros Medical
Neuros Medical, Inc.
10 patents
- Neurotrack
Neurotrack Technologies, Inc.
10 patents
- Neurotronic
Neurotronic, Inc.
10 patents
- Neutrolis
Neutrolis, Inc.
10 patents
- Neurmedix ◀
NeurMedix, Inc.
10 patents
What this shows NeurMedix holds 10 patents at rank #26,973, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near NeurMedix
By rank, the assignees closest to #26,973 in granted patent volume.
- Nauti-Craft Pty Ltd #26,969 · 10 patents
- Navinta, LLC #26,970 · 10 patents
- NejiLaw Inc. #26,971 · 10 patents
- NetBrain Technologies, Inc. #26,972 · 10 patents
- Neuros Medical, Inc. #26,974 · 10 patents
- Neurotrack Technologies, Inc. #26,975 · 10 patents
- Neurotronic, Inc. #26,976 · 10 patents
- Neutrolis, Inc. #26,977 · 10 patents
Leaders in C07J (Steroids)
Other assignees with the most granted patents in NeurMedix's primary technology class.
- Sage Therapeutics, Inc. 85 in class
- Intercept Pharmaceuticals, Inc. 39 in class
- Reata Pharmaceuticals Holdings, LLC 30 in class
- Enanta Pharmaceuticals, Inc. 20 in class
- Pop Test Oncology LLC 18 in class
- Brigham Young University 16 in class
- Bayer Intellectual Property GmbH 12 in class
- Arcturus Therapeutics, Inc. 12 in class
Neurmedix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
23 11th percentile higher than 11% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 30.0% |
| 2016 | 1 | 10.0% |
| 2017 | 3 | 30.0% |
| 2018 | 2 | 20.0% |
| 2021 | 1 | 10.0% |
Which technologies does NeurMedix, Inc. patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
NeurMedix, Inc.'s patent record in context - here's where to go next.
- NeurMedix, Inc.'s lead technology class is C07J (Steroids), 90% of its portfolio - see every assignee active in that class. Explore C07J
- Ranked #26,953 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare NeurMedix, Inc. against Nauti-Craft Pty Ltd, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 22.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.